1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Moleculin Biotech Acquires AnnaMed - Annamycin Rights

M&A Deal Summary

Moleculin Biotech Acquires AnnaMed - Annamycin Rights

On October 28, 2015, Moleculin Biotech acquired life science company AnnaMed - Annamycin Rights from AnnaMed

Acquisition Highlights
  • This is Moleculin Biotech’s 1st transaction in the Life Science sector.
  • This is Moleculin Biotech’s 1st transaction in the United States.

M&A Deal Summary
Date 2015-10-28
Target AnnaMed - Annamycin Rights
Sector Life Science
Buyer(s) Moleculin Biotech
Sellers(s) AnnaMed
Deal Type Divestiture

Target

AnnaMed - Annamycin Rights

United States
AnnaMed - Annamycin Rights is a provider of clinical stage drug research and services.

Search 214,600 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Moleculin Biotech

Houston, Texas, United States
Category Company
Sector Life Science
DESCRIPTION

Moleculin Biotech, Inc. is a clinical stage drug development company focused on cancer therapies based on breakthrough discoveries.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2015 M&A 1 of 1

Seller(S) 1

SELLER

AnnaMed

United States
Category Company
Sector Life Science
DESCRIPTION

AnnaMed, Inc. is a biotechnology company.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2015 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal